The Pharma Data

NOVEMBER 2, 2020

billion cumulative treatments to more than 923 million people since 2000. The treatments target the parasites in the blood of infected people and prevent the risk of transmission in the community. Setting sights on 2030. Despite setbacks due to COVID-19, WHO will accelerate work to achieve this target by 2030.

Packaging 52

Packaging Disease Treatment Drugs 52

The Pharma Data

APRIL 7, 2021

Additionally, Sanofi is committed to helping 1,000 patients living with rare diseases who have no access to treatments and will donate 100,000 vials of medicine for their treatments each year. Leveraging R&D efforts to address crucial treatment gaps. Zero plastic packaging for vaccines and ecodesign of products.

Packaging 52

Packaging Vaccine Disease Treatment 52

Agency IQ

MAY 10, 2024

In general, the law also pushes out a prohibition on almost all products with intentionally added PFAS from January 2030 to January 2032 , except for some cooling, heating, and refrigerant products which will be allowed until 2040.

Packaging 40

Packaging Regulations Production Compliance 40

Drug Discovery World

JULY 11, 2022

The global cell and gene therapy (CGT) market reached a value of ~$4 billion in 2020 and is expected to grow to ~$34 billion by 2030 1. Clinical trial sponsors need to coordinate the delivery of investigational medicinal products to clinical sites and the collection of samples from participants after they receive treatment. link] omtm.2021.04.001.

Therapies 130

Therapies Clinical Trials Production Trials 130

Drug Discovery World

FEBRUARY 10, 2023

This is reflected in the government’s aim of becoming a leader in the ATMP space by 2030. The positive response by Lokon Pharma is indicative of the service that Testa Center provides to companies ranging from academia to start-ups, to larger pharmaceutical companies.

Science 130

Science Drugs Pharmaceutical Companies Pharmaceuticals 130

Agency IQ

JUNE 28, 2024

In addition, the law prohibits the sale of carpets or fabric treatments containing PFAS as of January 1, 2023. In 2030, the law will ban the use of any product with intentionally added PFAS, unless the Maine legislature determines that the product currently serves an unavoidable use.

Production 40

Production Regulations Compliance Packaging 40

The Pharma Data

JANUARY 9, 2021

CDMO Services assumes continued growth in Development Services (DVS), Drug Substance (DS) manufacturing, and Drug Product (DP) manufacturing and Packaging for both clinical- and commercial-stage projects on behalf of a growing list of pharmaceutical and biotechnology innovators and government/NGO customers. FOOTNOTES. (1)

Government 52

Government Vaccine Production Licensing 52